Sun Pharmaceutical Industries Inc Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
Class II · Ongoing
Sep 19, 2017
Taro Pharmaceuticals U.S.A., Inc. Cross contamination with other products: traces of Dapsone were found in the finished product.
Class III · Terminated
Mar 16, 2017
Taro Pharmaceuticals U.S.A., Inc. Cross contamination with other products: Certain lots of Fluocinonide Cream were found to be contaminated with a small quantity of hydrocortisone-17-valerate.
Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).